Ann: Appendix 4D and Half Year Report, page-4

It Is what is not there that is tantalizing. Some encouraging pre-clinical results and boom - multi-bagger by end of March. Hints below -

Identify new clinical indications for which our proprietary ddRNAi-based genetic medicines have a highprobability of biological, clinical, and commercial successFollowing the recent restructuring of the management team, and the execution of the transformative research,development, and commercial partnership with Axovant Sciences, the senior leadership team of Benitec will workto redefine the core proprietary programs on which our efforts will focus.Benitec will provide additional details regarding the strategic direction of the research and development activitiesefforts of the Company during the first quarter of the 2019 calendar year.